Werewolf Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Werewolf Therapeutics

30/07/2025 14:26

Werewolf Therapeutics Inc HOWL.OQ HOWL.O is expected to  show a fall in quarterly revenue when it reports  results on August 1 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Werewolf Therapeutics Inc is for a loss of 48 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $9.00, about 85.6% above its last closing price of $1.30

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.44
-0.39
-0.40
Missed
-1.5
Dec. 31 2025
-0.47
-0.42
-0.46
Missed
-10
Sep. 30 2024
-0.42
-0.41
-0.38
Beat
7.8​
Jun. 30 2024
-0.40
-0.38
-0.40
Missed
-6.4
​​Mar. 31 2024
-0.33
-0.35
-0.39
Missed
-11.7
Dec. 31 2023
-0.43
-0.43
-0.33
Beat
23.9​
Sep. 30 2023
-0.40
-0.39
-0.23
Beat
41.7
Jun. 30 2023
-0.40
-0.42
-0.14
Beat
66.8

This summary was machine generated July 30 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)